Navigation Links
Minor shift in vaccine schedule has potential to reduce infant illness, death
Date:11/2/2008

years. Current recommendations also allow for administration of the first dose as early as 6 weeks of age, with the second and third doses at 3.5 months and 5.5 months.

The 2004 National Immunization Survey estimated that only 88 percent of infants had received one dose of DTaP vaccine by 3 months of age, 76 percent of infants had received two doses of DTaP vaccine by 5 months of age, and a mere 66 percent of infants had received the first three vital doses of DTaP vaccine by 7 months of age.

In this study, researchers sought to estimate the potential benefit of accelerating first dose administration from 2 months to 6 weeks of age.

"While two weeks may seem negligible, this change would reduce the time that a 2-month-old infant is completely without pertussis vaccine protection by 25 percent," Peters said. "Because pertussis so greatly threatens very young infants, the benefit of earlier vaccination may result in a significant decrease in severe pertussis disease nationally, and may be an especially useful approach during outbreaks of pertussis."

Researchers reviewed existing data to estimate current rates of pertussis infections, hospitalizations and deaths according to age and infant population in the United States in 2004. The data led researchers to expect that acceleration of the second and third doses by two weeks would prevent an additional 923 cases, 520 hospitalizations, and two deaths, according to the study.

Although administration of the first dose of the pertussis vaccine at 6 weeks of age is a change from the current routine practice of administration at 2 months, the minor dose acceleration falls within the current recommendations of the Advisory Committee on Immunization Practices and the American Academy of Pediatrics for the childhood vaccination schedule, and should have little impact on medical providers or on the number of outpatient physician visits for vaccines. All of the vaccines that are ro
'/>"/>

Contact: Jessica Guenzel
jguenzel@wfubmc.edu
336-716-3487
Wake Forest University Baptist Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Minorities more likely to have sleep durations associated with increased mortality
2. Johnson & Johnson Campaign for Nursings Future Joins With AACN to Offer New Minority Nurse Faculty Scholars Program
3. Eight Graduate Nursing Students Selected to Receive The California Endowment-AACN Minority Nurse Faculty Scholarship
4. USC receives $7.5M for Comprehensive Center of Excellence in Minority Health
5. Pressure to Promote Healthier Eating to Cause Minor Growing Pains for Kids Licensed Foods and Beverages
6. Contents of the McGinnis Mansion Refurbishes Portland, Oregon Sexual Minority Youth Center
7. SIAD Healthcare S.p.A. Acquires Minority Ownership in GENICON
8. Patient navigators help minority, low-income cancer patients get life-saving treatments
9. Minority patients prefer optical colonoscopy for colorectal cancer screening
10. New technique to determine the age of immigrant minors through ribs and teeth
11. Study of minority New York City youth finds unequal burden of poor dental health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... Washington, DC (PRWEB) April 21, 2015 ... operations and Information Technology advisory firm that helps ... technological change, today announced that the Association ... Optimity a Preferred Vendor. ACAP represents 58 local, ... serve more than 13 million people primarily enrolled ...
(Date:4/21/2015)... FL (PRWEB) April 21, 2015 AxoGen, ... on the peripheral nerve repair market, will report results ... 5, 2015 following the close of the market. ... webcast for the investment community following the release at ... phone are invited to call toll free at 1.877.407.0993 ...
(Date:4/21/2015)... April 21, 2015 The PracticeMatch Career ... 5:00 to 8:00 pm at the William and Ida Friday ... NC 27599. More than 50 hospitals, clinics and groups with ... specialties will be represented. Attendees will enjoy free hors d’oeuvres ... Fairs for PracticeMatch says “Chapel Hill is an ...
(Date:4/21/2015)... With a growing number of Americans retiring abroad, ... international political instability and terrorism top the list of ... a global insurance provider with 68 years’ experience covering ... citizenship, also found strong concern but lack of information ... overseas . , Asked to choose the risks of ...
(Date:4/21/2015)... Pharmacy point of sale software ... Independent Pharmacy Cooperative trade show, to be held April ... , Retail Management Solutions recently became an approved vendor ... Gross, VP of Sales and Marketing. Gross says that ... trade shows in the country -- and this new ...
Breaking Medicine News(10 mins):Health News:Optimity Advisors Named Preferred Vendor by the Association of Community Affiliated Plans (ACAP) 2Health News:AxoGen, Inc. to Report First Quarter Financial Results on May 5, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 2Health News:PracticeMatch to Host Physician Career Fair at William and Ida Friday Center at UNC-Chapel Hill on April 29, 2015 3Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 2Health News:Potential Expatriate Retirees Fear Political Violence, International Health Insurance Coverage 3Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 2Health News:Retail Management Solutions to Attend Upcoming Independent Pharmacy Cooperative Trade Show 3
... 30 Neogen Corporation,(Nasdaq: NEOG ) announces the following Webcast: , ... When: Tuesday, January 6, 2009 @ 11:00 EST, ... Live over the Internet -- Simply log on to the web at ... above., Contact: Terry Maynard of Neogen Corporation, +1-800-234-5333., , ...
... called "the world,s first disposable hearing aid", and is designed ... needing part-time hearing assistance. , ... ... being called "the world,s first disposable hearing aid", and is ...
... impulsive people, New Year,s resolutions often include being ... on dangerous behavior, such as drug use. But ... as novelty seekers by psychologists--face an uphill battle ... the way their brains process dopamine. The research ...
... YORK and BIRMINGHAM, Ala., Dec. 29 Health,Systems Solutions, Inc. ... ) today announced that they have agreed to extend the ... "We are pleased that, with the ... timetable for the completion of the merger and we are ...
... Dec. 29 Curious about your child,s diet,preventing ... or daughter has a sports-related,injury? , ... youth sports coaches, parents and,athletes focused on education, ... Spine (PEAKOrthopedics.com) to answer these questions,through an online, ...
... have lower risks of Alzheimer,s disease and other cognitive ... In more than half of the studies, published since ... had lower dementia risks than nondrinkers. In only a ... a two-edged sword," said Michael Collins, Ph.D., a professor ...
Cached Medicine News:Health News:Supple, Hi-Flex Cable from Cicoil Makes First Disposable Hearing Aid Possible 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Health Systems Solutions and Emageon Extend Merger Closing 2Health News:Health Systems Solutions and Emageon Extend Merger Closing 3Health News:SportZu.tv Partners With PEAK Orthopedics & Spine to Launch an Online Sports Doctor's Office 2Health News:Moderate drinking can reduce risks of Alzheimer's dementia and cognitive decline 2
(Date:4/21/2015)... 2015 EUSA Pharma (EUSA), a ... announced the appointment of Lee Morley as ... Non-Executive Director.  Bryan Morton, who established EUSA Pharma as ... Lee Morley joins from Jazz ... of Commercial for Europe and ...
(Date:4/20/2015)... KUALA LUMPUR, Malaysia , April 20, 2015 /PRNewswire/ ... 2015, resulting in a scarcity of opportunities for generic ... drug manufacturers in the region are looking beyond the ... the quality of existing drugs. Certain established generic manufacturers ... research and development of new molecules, although the impact ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes the ... following Product Segments: Non-Powered Breast Pumps, and Powered Breast Pumps. ... Canada , Japan , ... Rest of World. Annual estimates and forecasts are provided for ... is provided for these markets. Market data and analytics are ...
Breaking Medicine Technology:EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 2EUSA Pharma Appoints Lee Morley as Chief Executive and Industry Veteran Göran Ando to Board of Directors 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14
... NEW YORK, Oct. 6 Reportlinker.com announces ... available in its catalogue. , ... Pharma and Biotech , ... The Drug Delivery Partnering Agreements in Pharma ...
... N.J., Oct. 6 Centocor Ortho Biotech Inc. and ... the European Commission has approved SIMPONI(TM) (golimumab) as a ... rheumatoid arthritis (RA), active and progressive psoriatic arthritis (PsA) ... In the European Union, SIMPONI is approved as a ...
Cached Medicine Technology:Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 2Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 3Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 4Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 5Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 6Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 2SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 3SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 4SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 5SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 6SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 7SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 8SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 9SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector 10
... to introduce the Cmax operating table that ... general surgical table with the radiolucence and ... it the most advanced, versatile surgical table ... designed to support advancements in surgical procedures ...
... urology imaging table is a fully digital ... imaging and advanced patient data management system. ... in the industry providing unsurpassed access for ... changed to either a right- or left- ...
Inquire...
... Elevated Immunosuppressant Control is a bilevel Cyclosporine ... This unique product is ideal for use ... Cyclosporine levels, such as C2 monitoring, which ... two hours post-dose., ,Lyphochek Elevated Immunosuppressant Control ...
Medicine Products: